Arcosa, Inc. Announces Fourth Quarter and Full Year 2018 Results and Increases 2019 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- Outlook Therapeutics (OTLK) halted, news pending
- Nasdaq lags on angst over AI spending ahead of earnings reports
Arcosa (ACA) Tops Q4 EPS by 12c; Raises Outlook
February 27, 2019 4:16 PM ESTArcosa (NYSE: ACA) reported Q4 EPS of $0.40, $0.12 better than the analyst estimate of $0.28. Revenue for the quarter came in at $374.4 million versus the consensus estimate of $358.55 million.
GUIDANCE:
Raises full year 2019 adjusted EBITDA guidance to a range of $215 million to $225 million following... More
